Basal cell carcinoma is the most common malignant skin cancer in whites, and the US alone sees an estimated 3.6 million cases diagnosed every year. Yet the statistics look very different depending on subtype, from eczema like superficial patches to nodular lesions with arborizing vessels, and survival nearly always hinges on how early it is found. This post pulls together the key BCC numbers, including rates, diagnostic accuracy, recurrence patterns, and risk factors, so you can see exactly where the biggest shifts happen.
Key Takeaways
- Basal cell carcinoma typically presents as a pearly nodule with telangiectasia on sun-exposed skin, most commonly on the face (80% of cases).
- Nodular BCC subtype accounts for 60-80% of cases, characterized by rolled borders and central ulceration.
- Superficial BCC appears as erythematous patches resembling eczema, comprising 15-20% of BCCs.
- Basal cell carcinoma (BCC) represents about 80% of all malignant skin tumors in whites, with an estimated 3.6 million cases diagnosed annually in the US.
- The incidence rate of BCC in the US has increased by over 10% per year since 1994, reaching 43.6 cases per 100,000 person-years by 2012.
- In Australia, BCC incidence is the highest globally at 1,015 per 100,000 person-years in men and 624 in women aged 60-69.
- Basal cell carcinoma has a 99% 5-year survival rate when detected early and treated appropriately.
- Local recurrence rate for incompletely excised BCC is 39% at 5 years with no further treatment.
- Metastatic BCC occurs in <0.1% cases, with median survival 8-10 months post-metastasis.
- Ultraviolet radiation exposure is the primary risk factor for basal cell carcinoma, responsible for up to 90% of cases in fair-skinned individuals.
- Fair skin (Fitzpatrick types I-II) increases BCC risk by 2-3 fold compared to darker skin types.
- History of severe sunburns before age 20 doubles the lifetime BCC risk.
- Surgical excision with 4mm margins clears 98% of low-risk BCCs (Mohs preferred for high-risk).
- Mohs micrographic surgery achieves 99% cure rate for primary BCC, 94% for recurrent.
- Topical imiquimod 5% cream cures 82-90% superficial BCCs after 6-12 weeks.
Basal cell carcinoma is the most common skin cancer, with rapid global growth and usually curable early.
Related reading
01 · Category
Diagnosis and Pathology27 stats
01
Basal cell carcinoma typically presents as a pearly nodule with telangiectasia on sun-exposed skin, most commonly on the face (80% of cases).
02
Nodular BCC subtype accounts for 60-80% of cases, characterized by rolled borders and central ulceration.
03
Superficial BCC appears as erythematous patches resembling eczema, comprising 15-20% of BCCs.
04
Dermoscopy shows arborizing vessels in 90% of nodular BCCs, aiding diagnosis accuracy to 93%.
05
Histopathology reveals peripheral palisading basaloid cells with retraction artifact in 95% of BCCs.
06
Morpheaform/sclerosing BCC (5-10%) presents as scar-like plaque, often missed clinically.
07
Average BCC size at diagnosis is 6-10 mm, but infiltrative types average larger at 15 mm.
08
Head and neck BCCs constitute 85%, with nose (25%), cheek (20%), and eyelid (10%) most common sites.
09
Pigmented BCC (variant, 6-8%) mimics melanoma with blue-black pigmentation.
10
Biopsy sensitivity for BCC diagnosis is 98%, with punch biopsy preferred for small lesions.
11
PTCH1 gene mutations detected in 67% of sporadic BCCs via sequencing.
12
Ultrasound shows hypoechoic lesions with ill-defined borders in infiltrative BCC (sensitivity 89%).
13
Cystic BCC (2-3%) appears as shiny translucent nodule with bluish hue.
14
Average age at BCC diagnosis is 66 years, with rare pediatric cases in syndromes.
15
H&E staining shows mucin pools in 40% of BCCs, confirming diagnosis.
16
Reflectance confocal microscopy achieves 90% diagnostic accuracy non-invasively for BCC.
17
Basosquamous carcinoma (mixed BCC/SCC, 1-2%) shows aggressive biphasic histology.
18
Fibroepithelioma of Pinkus (rare BCC variant) presents as pink pedunculated lesion on back.
19
Ki-67 proliferation index is low (<5%) in most BCCs, distinguishing from high-grade tumors.
20
Optical coherence tomography (OCT) detects BCC with 95% sensitivity, showing disrupted architecture.
21
Micronodular BCC (5%) has small nests without retraction, mimicking morpheaform.
22
BCC recurrence suspected if lesion >2cm, recurrent, or incompletely excised (risk 10-20%).
23
BerEP4 immunohistochemistry positive in 100% BCCs, aiding differentiation from SCC.
24
Adamantinoid BCC variant shows peripheral clefting with central eosinophilic material.
25
Sentinel lymph node biopsy rarely positive (<1%) in BCC, not routinely recommended.
26
Mean duration of BCC before diagnosis is 12-18 months for nodular type.
27
Infundibulocystic BCC presents as flesh-colored papule with comedo-like opening.
Interpretation
Diagnosis and Pathology Interpretation
While your average sun-worshipper might spend years perfecting a golden tan, the skin on their face is quietly and meticulously conducting a masterclass in subtle, varied, and often deceptively innocent-looking rebellion, with pearly nodules and eczema-like patches being its preferred methods of insurrection.
02 · Category
Epidemiology30 stats
01
Basal cell carcinoma (BCC) represents about 80% of all malignant skin tumors in whites, with an estimated 3.6 million cases diagnosed annually in the US.
02
The incidence rate of BCC in the US has increased by over 10% per year since 1994, reaching 43.6 cases per 100,000 person-years by 2012.
03
In Australia, BCC incidence is the highest globally at 1,015 per 100,000 person-years in men and 624 in women aged 60-69.
04
Lifetime risk of developing BCC is 28-33% for men and 23-28% for women in high-risk populations like the US white population.
05
BCC prevalence in the UK elderly (>75 years) exceeds 50%, with over 100,000 new cases yearly.
06
Global BCC incidence varies from 32.4 per 100,000 in Singapore to 1,298 per 100,000 in Queensland, Australia.
07
In the US, men have a 1.5 times higher BCC incidence rate than women, at 52 vs 34 per 100,000.
08
BCC accounts for 75-80% of non-melanoma skin cancers (NMSC) worldwide, with rising trends in all age groups.
09
Danish cohort study shows BCC incidence doubled from 1968-2006, from 26 to 53 per 100,000.
10
In fair-skinned populations, BCC age-standardized incidence rate is 35-50 per 100,000 annually.
11
US Medicare data (2006-2010) reports 2.2 million BCC treatments yearly, indicating high burden.
12
BCC is the most common cancer in the US, with over 4 million cases yearly by 2020 estimates.
13
Incidence of BCC on the trunk has increased 230% from 1976-2005 in US veterans.
14
European standardized incidence of BCC rose from 30 to 60 per 100,000 between 1997-2008.
15
In Canada, BCC incidence is 145 per 100,000 in men and 98 in women.
16
Lifetime BCC risk in US Caucasians is 1 in 3 for men and 1 in 4 for women.
17
BCC rates in Sweden increased 60% in men and 30% in women from 1984-2012.
18
High UV regions like New Zealand report BCC incidence up to 1,700 per 100,000 in elderly males.
19
US SEER data shows BCC incidence 33.7 per 100,000 for whites vs 0.5 for blacks.
20
Annual global BCC cases estimated at 2.8 million, comprising 70% of skin cancers.
21
In Italy, BCC incidence stabilized at 90 per 100,000 after rising in prior decades.
22
BCC is diagnosed in 1 out of every 5 Americans over their lifetime.
23
Norwegian registry reports 1,200 new BCC cases per 100,000 person-years in ages 70+.
24
BCC incidence in China is rising rapidly, from 0.8 to 2.5 per 100,000 (2008-2018).
25
US veterans have 1.4-fold higher BCC risk, with 1.2 million cases in 2010-2019.
26
In the Netherlands, BCC incidence reached 170 per 100,000 in 2017.
27
BCC comprises 95% of head/neck skin cancers in sunny climates.
28
Lifetime multiple BCC risk is 50% after first diagnosis in US whites.
29
Brazilian study shows BCC incidence 24.5 per 100,000, highest in South region.
30
UK GP data indicates 147,000 BCC diagnoses in 2017, up 20% from 2012.
Interpretation
Epidemiology Interpretation
The stats paint a clear, sun-damaged picture: basal cell carcinoma is not a rare anomaly but a global epidemic of the most common human cancer, spreading faster than sunscreen on a windy beach.
03 · Category
Prognosis and Prevention29 stats
01
Basal cell carcinoma has a 99% 5-year survival rate when detected early and treated appropriately.
02
Local recurrence rate for incompletely excised BCC is 39% at 5 years with no further treatment.
03
Metastatic BCC occurs in <0.1% cases, with median survival 8-10 months post-metastasis.
04
5-year recurrence-free survival after Mohs surgery is 97% for primary facial BCC.
05
High-risk BCC (morpheaform, >2cm) recurs 20-25% after standard excision.
06
Daily sunscreen SPF 30+ reduces BCC risk by 40% in high-risk individuals (Nambour trial).
07
Patients with one BCC have 44% risk of second within 3 years, 60% by 5 years.
08
Mortality from invasive BCC is 0.002%, mainly from neglect (775 US deaths/year).
09
Nicotinamide 500mg BID reduces new BCCs by 20% in prior NMSC patients (ONTRAC trial).
10
UV avoidance and hats reduce BCC incidence 50% in occupational settings.
11
10-year local control after radiotherapy is 90% for BCC <5cm.
12
Gorlin syndrome patients have 35% risk of aggressive BCC by age 20.
13
Aspirin use >325mg/day reduces NMSC risk including BCC by 20-30% (cohort study).
14
Self-skin exam monthly detects BCC earlier, reducing size by 30% at diagnosis.
15
Vismodegib median PFS 9.5 months in metastatic BCC (ERIVANCE trial).
16
Retinoids (acitretin) reduce new BCCs 30% in high-risk patients.
17
5-year survival for metastatic BCC is 10-15% with systemic therapy.
18
Annual dermatology screening reduces second BCC incidence by 25%.
19
Shade provision lowers BCC risk 50% in recreational sun exposure.
20
Perineural invasion in BCC worsens prognosis, recurrence 47% vs 11% without.
21
Beta-carotene supplements ineffective, no reduction in BCC incidence.
22
UPF clothing (50+) prevents 98% UVB, reducing BCC risk long-term.
23
Immunosuppressed patients have 10% annual new BCC rate post-transplant.
24
Selenium supplements show no benefit in BCC prevention (SELECT trial).
25
Early excision (<6 months) halves recurrence risk vs delayed.
26
Vitamin E topical/oral does not prevent BCC development.
27
AI-assisted dermoscopy improves BCC detection sensitivity to 95%.
28
Sirolimus topical reduces new BCCs in transplant patients by 44%.
29
Lifetime sun protection factor (SPF cumulative) inversely correlates with BCC count.
Interpretation
Prognosis and Prevention Interpretation
While the statistics paint an almost cartoonishly low mortality risk, they simultaneously build a compelling, urgent case that your laziness about sunscreen and check-ups is a surefire recipe for decades of inconvenient, disfiguring, and expensive surgeries.
More related reading
04 · Category
Risk Factors28 stats
01
Ultraviolet radiation exposure is the primary risk factor for basal cell carcinoma, responsible for up to 90% of cases in fair-skinned individuals.
02
Fair skin (Fitzpatrick types I-II) increases BCC risk by 2-3 fold compared to darker skin types.
03
History of severe sunburns before age 20 doubles the lifetime BCC risk.
04
Chronic sun exposure, especially intermittent intense exposure, raises BCC odds ratio to 2.7 (95% CI 1.8-4.1).
05
Immunosuppression from organ transplant increases BCC risk 10-fold within 10 years post-transplant.
06
Family history of skin cancer elevates BCC risk by 1.9 times (RR 1.9, 95% CI 1.6-2.2).
07
Male gender confers 1.5-2.0 higher BCC incidence rate than females across all ages.
08
Age over 60 years increases BCC risk exponentially, with peak incidence at 70-80 years.
09
Use of tanning beds before age 35 increases BCC risk by 75% (OR 1.75, 95% CI 1.35-2.26).
10
Arsenic exposure in drinking water >100 μg/L raises BCC risk 2.5-fold.
11
Psoralen-UVA phototherapy (PUVA) for psoriasis increases BCC risk by 6.3% per year of treatment.
12
Blue or green eyes combined with blonde/red hair triples BCC susceptibility.
13
HIV infection elevates NMSC risk, including BCC, by 3-fold (SIR 3.3).
14
Ionizing radiation exposure (e.g., radiotherapy) increases BCC risk in treated field by 2-5 times.
15
Genetic syndromes like Gorlin syndrome (PTCH1 mutation) cause 90% lifetime BCC risk by age 40.
16
Occupational outdoor work raises BCC risk 1.5-2.0 fold due to cumulative UV.
17
MC1R gene variants increase BCC risk 2-4 fold in Europeans.
18
Smoking is inversely associated, reducing BCC risk by 20-30% (OR 0.7-0.8).
19
Prior NMSC history increases subsequent BCC risk 40-fold within first year.
20
Vitamin D deficiency does not directly increase BCC risk but correlates with sun avoidance.
21
HPV infection (certain strains) may synergize with UV to elevate BCC risk 1.5-fold.
22
Obesity (BMI>30) slightly increases BCC risk on trunk (OR 1.3).
23
Alcohol consumption >20g/day raises BCC risk marginally (RR 1.1).
24
Xeroderma pigmentosum patients have 1,000-fold higher BCC risk due to DNA repair defects.
25
Basal cell nevus syndrome patients develop >100 BCCs lifetime, starting age 8 average.
26
Chronic non-healing wounds or scars increase BCC risk (Marjolin ulcer).
27
P53 gene mutations from UV are found in 50-60% of BCCs, linking to risk.
28
Living at high altitude (>1,000m) increases BCC risk 1.4-fold per 1,000m elevation.
Interpretation
Risk Factors Interpretation
While the sun might be a generous giver of light and life, this data proves it’s a fickle friend, making our own skin the primary traitor in a plot where fair complexions, youthful sunburns, and modern tanning habits are the most predictable co-conspirators against our long-term health.
05 · Category
Treatment26 stats
01
Surgical excision with 4mm margins clears 98% of low-risk BCCs (Mohs preferred for high-risk).
02
Mohs micrographic surgery achieves 99% cure rate for primary BCC, 94% for recurrent.
03
Topical imiquimod 5% cream cures 82-90% superficial BCCs after 6-12 weeks.
04
Curettage and electrodesiccation effective for low-risk BCC <1cm, 95% 5-year cure rate.
05
Cryotherapy with liquid nitrogen achieves 88-99% success for superficial/nodular BCC <2cm.
06
Photodynamic therapy (PDT) with ALA cures 78% superficial BCC at 12 months.
07
Vismodegib (Hedgehog inhibitor) shrinks advanced BCC in 43% (ORR), for metastatic/locally advanced.
08
Radiation therapy used for nonsurgical candidates, 5-year local control 92-97%.
09
5-Fluorouracil (5-FU) 5% cream effective for superficial BCC, 80% response rate.
10
Sonidegib oral therapy shows 56% objective response in locally advanced BCC.
11
Sentinel lymph node dissection indicated rarely, with completion lymphadenectomy if positive.
12
Topical ingenol mebutate 0.015% for superficial BCC, 70% histological clearance.
13
Laser ablation (CO2) for periocular BCC achieves 96% clearance with low recurrence.
14
Cemiplimab (PD-1 inhibitor) for advanced CSCC but used off-label in BCC, ORR 50%.
15
Intralesional 5-FU for periocular BCC shows 100% response in small series.
16
Hyntude (patidegib) topical gel prevents new BCCs in Gorlin syndrome (phase 2).
17
Electrodesiccation alone for superficial BCC <1cm has 97% 5-year success.
18
Pembrolizumab for metastatic BCC shows 33% response in hedgehog-resistant cases.
19
Neoadjuvant vismodegib allows surgery in 68% unresectable BCC cases.
20
Shave excision for nodular BCC <1cm has 94-97% clearance rate.
21
Topical methylaminolevulinic acid-PDT cures 89% nodular BCC <2mm.
22
Systemic itraconazole inhibits hedgehog pathway, 24% response in advanced BCC.
23
Brachytherapy for facial BCC achieves 96.6% local control at 2 years.
24
Combination vismodegib + radiation improves response in advanced disease.
25
Talimogene laherparepvec (T-VEC) experimental for BCC immunotherapy.
26
Microcystic adnexal carcinoma mimic requires Mohs (99% cure).
Interpretation
Treatment Interpretation
Navigating basal cell carcinoma treatment is like choosing from a well-stocked toolbox: you can reliably fix most spots with a standard surgical wrench, but for the tricky, high-stakes jobs you'll want Mohs' precision microscope, and thankfully there's even a growing shelf of specialized options when the usual tools won't do.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Basal Cell Carcinoma Statistics. Gitnux. https://gitnux.org/basal-cell-carcinoma-statistics
MLA
James Okoro. "Basal Cell Carcinoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/basal-cell-carcinoma-statistics.
Chicago
James Okoro. 2026. "Basal Cell Carcinoma Statistics." Gitnux. https://gitnux.org/basal-cell-carcinoma-statistics.
Sources & references
18 datasets cited across this report · attribution is report-level